Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer
FDA engagement signals cautious progress for AEON Biopharma Inc. in complex biologics space (NYSE American: AEON)
Read More 5 minute read Pharma Industry News Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer IMNN-001 plus PARP inhibitors shows extended survival in ovarian cancer. Find out what this means for IMUNON Inc. and future treatment strategies. bySoujanya RaviMarch 28, 2026